A detailed history of Hallmark Capital Management Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Hallmark Capital Management Inc holds 45,796 shares of GILD stock, worth $4.18 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares
45,796
Previous 46,524 1.56%
Holding current value
$4.18 Million
Previous $3.19 Million 20.24%
% of portfolio
0.29%
Previous 0.26%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

SELL
$66.59 - $83.99 $48,477 - $61,144
-728 Reduced 1.56%
45,796 $3.84 Million
Q2 2024

Aug 08, 2024

SELL
$63.15 - $72.88 $210,226 - $242,617
-3,329 Reduced 6.68%
46,524 $3.19 Million
Q1 2024

May 03, 2024

SELL
$71.58 - $87.29 $297,343 - $362,602
-4,154 Reduced 7.69%
49,853 $3.65 Million
Q4 2023

Feb 07, 2024

BUY
$73.27 - $83.09 $61,326 - $69,546
837 Added 1.57%
54,007 $4.38 Million
Q3 2023

Nov 09, 2023

SELL
$73.94 - $80.67 $114,089 - $124,473
-1,543 Reduced 2.82%
53,170 $3.98 Million
Q2 2023

Jul 28, 2023

SELL
$76.01 - $86.7 $217,996 - $248,655
-2,868 Reduced 4.98%
54,713 $4.22 Million
Q1 2023

May 03, 2023

SELL
$77.31 - $88.08 $285,892 - $325,719
-3,698 Reduced 6.03%
57,581 $4.78 Million
Q4 2022

Feb 01, 2023

SELL
$62.32 - $89.47 $94,477 - $135,636
-1,516 Reduced 2.41%
61,279 $5.26 Million
Q3 2022

Nov 09, 2022

BUY
$59.54 - $68.01 $38,224 - $43,662
642 Added 1.03%
62,795 $3.87 Million
Q2 2022

Nov 16, 2022

SELL
$57.72 - $65.01 $37,056 - $41,736
-642 Reduced 1.02%
62,153 $3.84 Million
Q2 2022

Aug 01, 2022

BUY
$57.72 - $65.01 $228,744 - $257,634
3,963 Added 6.81%
62,153 $3.84 Million
Q1 2022

May 02, 2022

BUY
$57.92 - $72.58 $335,993 - $421,036
5,801 Added 11.07%
58,190 $3.46 Million
Q4 2021

Feb 02, 2022

BUY
$64.88 - $73.64 $49,179 - $55,819
758 Added 1.47%
52,389 $3.8 Million
Q3 2021

Nov 01, 2021

SELL
$67.69 - $73.03 $7,784 - $8,398
-115 Reduced 0.22%
51,631 $3.61 Million
Q2 2021

Aug 03, 2021

BUY
$63.47 - $69.35 $257,053 - $280,867
4,050 Added 8.49%
51,746 $3.56 Million
Q1 2021

Apr 22, 2021

BUY
$60.0 - $68.46 $332,100 - $378,926
5,535 Added 13.13%
47,696 $3.08 Million
Q4 2020

Feb 02, 2021

BUY
$56.65 - $64.55 $242,122 - $275,886
4,274 Added 11.28%
42,161 $2.46 Million
Q3 2020

Nov 03, 2020

BUY
$62.1 - $78.08 $245,419 - $308,572
3,952 Added 11.65%
37,887 $2.39 Million
Q2 2020

Jul 28, 2020

SELL
$72.34 - $84.0 $244,509 - $283,920
-3,380 Reduced 9.06%
33,935 $2.61 Million
Q1 2020

Apr 24, 2020

SELL
$62.63 - $80.22 $33,945 - $43,479
-542 Reduced 1.43%
37,315 $2.79 Million
Q4 2019

Jan 31, 2020

BUY
$61.62 - $67.78 $237,052 - $260,749
3,847 Added 11.31%
37,857 $2.46 Million
Q3 2019

Nov 01, 2019

SELL
$62.51 - $69.0 $18,127 - $20,010
-290 Reduced 0.85%
34,010 $2.16 Million
Q2 2019

Aug 08, 2019

BUY
$61.87 - $69.38 $329,767 - $369,795
5,330 Added 18.4%
34,300 $2.32 Million
Q1 2019

May 09, 2019

BUY
$62.53 - $70.05 $387,060 - $433,609
6,190 Added 27.17%
28,970 $1.88 Million
Q4 2018

Feb 08, 2019

SELL
$60.54 - $79.0 $403,196 - $526,140
-6,660 Reduced 22.62%
22,780 $1.43 Million
Q3 2018

Oct 26, 2018

BUY
$71.28 - $78.92 $157,172 - $174,018
2,205 Added 8.1%
29,440 $2.27 Million
Q2 2018

Aug 02, 2018

BUY
$64.88 - $75.68 $21,086 - $24,596
325 Added 1.21%
27,235 $1.93 Million
Q1 2018

Apr 27, 2018

BUY
$72.84 - $88.8 $67,741 - $82,584
930 Added 3.58%
26,910 $2.03 Million
Q4 2017

Jan 24, 2018

BUY
$71.15 - $83.52 $43,401 - $50,947
610 Added 2.4%
25,980 $1.86 Million
Q3 2017

Oct 30, 2017

BUY
$72.11 - $85.47 $1.83 Million - $2.17 Million
25,370
25,370 $2.06 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $114B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Hallmark Capital Management Inc Portfolio

Follow Hallmark Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hallmark Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Hallmark Capital Management Inc with notifications on news.